Browsing Tag
Mass General Brigham
7 posts
Humacyte’s dialysis bet gains momentum, but $0.71 stock still reflects major execution risk
HUMA jumps 22% as peer-reviewed ATEV Phase 3 data strengthen Humacyte’s planned FDA filing for a potentially much larger dialysis market.
CPSC emergency-room data push sparks privacy alarm over millions of identifiable records
Hospitals are challenging a federal push for identifiable emergency-room records. See why the CPSC data plan is raising privacy alarms.
Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing
Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.
Neurizon Therapeutics (ASX: NUZ) NUZ-001 activates dual protein clearance pathways in ALS neuronal study
Neurizon Therapeutics NUZ-001 activates two protein clearance pathways in ALS neurons. Read what the preclinical data means ahead of the HEALEY trial.
NeuroSense Therapeutics (NASDAQ: NRSN) advances PrimeC development after JAMA Neurology publishes PARADIGM Phase 2b ALS trial results
JAMA Neurology publishes PARADIGM trial results showing PrimeC slowed ALS decline. Discover what this means for NeuroSense Therapeutics’ Phase 3 plans.
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.
Microsoft partners with top medical institutions to revolutionise radiology with AI
Microsoft Corp. has unveiled collaborations with leading academic medical institutions Mass General Brigham, the University of Wisconsin School…